CLINICAL EVALUATION OF SULBACTAM/CEFOPERAZONE IN THE FIELD OF RESPIRATORY TRACT INFECTIONS

Abstract

Sulbactam/Cefoperazone (SBT/CPZ) was administered to 10 patients with respiratory tract infections, who had responded poorly to treatment with other antibiotics, at dose level of 1 g twice daily by drip infusion. The overall clinical effectiveness rate was 70%(7/10).
One of the two patients with chronic bronchitis who had poorly responded to Cefoperazone was responded with good result to the combination drug. Causative organism of the non-responded case was identified as E. coil, that produced β-lactamase highly and was resistant to cefoperazone (MIC: 100μg/rill).
Neither subjective adverse reactions nor abnormal laboratory findings related to the drug were observed.
Thus, it is suggested that SBT/CPZ is a useful drug for the treatment of RTI, especially chronic complicated lower respiratory tract infections, and further evaluation in this field, for instance transfer of the drug to pulmonary tissue, would be worthwhile.